Incyte Corp.

NASDAQ:INCY  
65.78
-0.85 (-1.28%)
Products

Incyte Announces U.S. FDA Has Extended The New Drug Application Review Period For Ruxolitinib Cream For The Treatment Of Atopic Dermatitis

Published: 06/11/2021 12:50 GMT
Incyte Corp. (INCY) - Incyte Announces U.S. FDA Has Extended the New Drug Application Review Period for Ruxolitinib Cream for the Treatment of Atopic Dermatitis.
Incyte Announces U.S. FDA Has Extended the New Drug Application Review Period for Ruxolitinib Cream for the Treatment of Atopic Dermatitis.
Incyte Corp - Prescription Drug User Fee Act (pdufa) Action Date Has Been Extended by Three Months to September 21, 2021.
Incyte - FDA Extended PDUFA Date to Allow Time to Review Additional Analyses of Previously Submitted Data Provided in Response to FDA's Request.